

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

20th November, 2025

To,

**The Corporate Relationship Department
BSE Limited**

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001.

Scrip Code: 539523

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra East ,
Mumbai 400 051.

Scrip Symbol: ALKEM

Sub: Press Release – Alkem launches probiotic “DSS”, the original De Simone formulation, in India for gut health management

Dear Sir(s)/Madam,

This is to intimate you that Alkem Laboratories Limited (the “Company”) launches probiotic “DSS”, the original De Simone formulation, in India for gut health management.

A press release in this regard is enclosed herewith.

Kindly take the same on record.

Sincerely,

For **Alkem Laboratories Limited**

Manish Narang

President- Legal, Company Secretary and Compliance Officer

Press Release

Alkem launches probiotic “DSS”, the original De Simone formulation, in India for gut health management

Mumbai, November 20, 2025: Alkem Laboratories Ltd. (BSE: 539523, NSE: ALKEM, “Alkem” and its subsidiaries) today announced the launch of DSS, the original De Simone formulation probiotic blend in India for restoring gut microbiota balance and managing various gut-related health conditions.

Developed by Prof. Claudio De Simone, this proprietary probiotic combines eight carefully selected bacterial strains in precise proportions, chosen for their distinct biochemical and enzymatic profile, to act synergistically on the physiology of the gastrointestinal system.

The De Simone formulation is recognised as one of the world’s most extensively researched probiotics, backed by over 80 clinical trials and 200 publications over the last two decades. It is also endorsed by leading American and European gastroenterology associations in their guidelines for managing gastrointestinal disorders. Alkem has in-licensed these formulations from Next Gen Pharma India Pvt. Ltd.

Alkem’s DSS range will be available in four strengths – 225 billion CFU sachet, 112.5 billion CFU capsule, 45 billion CFU capsule, and 10 billion CFU capsule – providing healthcare professionals and patients with tailored options to manage a wide spectrum of gastrointestinal conditions. Alkem is the first company offering all four strengths of this probiotic in India and also the first to launch 225 billion CFU and 10 billion CFU strengths in India, for which it has exclusive marketing rights.

The DSS probiotic contains eight live, freeze-dried bacterial strains – four Lactobacillus, three Bifidobacterium and one Streptococcus – that work to help restore gut microbiota balance and deliver proven clinical benefits.

DSS is indicated for the management of various disorders such as Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC), Pouchitis, Hepatic Encephalopathy (HE), Non-Alcoholic Fatty Liver Disease (NAFLD), Cirrhosis, Bacterial Vaginosis (BV), Antibiotic-Associated Diarrhea (AAD), and other gut dysbiosis-related conditions, as well as for supplementation during pregnancy and lactation.

Dr. Vikas Gupta, Chief Executive Officer, Alkem, said, “There is a growing focus on managing gut health as an integral part of overall well-being, and probiotics have emerged as a key enabler in this space. The launch of DSS, a globally-trusted, high-potent, multi-strain probiotic, is a strategic addition to our comprehensive product portfolio in the gastrointestinal segment, and underscores our commitment to making innovative and evidence-based health solutions accessible to Indian patients.”

Demand for probiotics in India continues to grow, driven by increasing consumer awareness and rising prevalence of lifestyle-related digestive issues. According to IQVIA data (MAT October 2025), the prescription probiotic market in India is valued at around INR 2,071 crore, and has recorded a five-year CAGR of approximately 14%.

About Alkem:

Alkem Laboratories Ltd. is a leading Indian pharmaceutical company with a legacy of 50 years in providing high quality medicines to patients. It is the fifth largest pharmaceutical company in the Indian market with a dominant position in the therapy areas of anti-infectives, gastrointestinal, pain management drugs and supplements. It also has a growing portfolio of products in chronic therapies such as diabetes, neurology, cardiology, dermatology and urology. It has 19 state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centers across India and the US to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has meaningful presence in the US, Latin America, Australia and several Asian countries. “Inspiring Healthier Lives” is at the core of the values and culture of the organisation and reinforces its steadfast commitment to global health improvement. For more information, please visit www.alkemlabs.com and follow us on [LinkedIn](#), [Instagram](#), [Facebook](#).

Contacts

Media:	Investors:
Isha Trivedi	Purvi Shah
alkemcorpcomm@alkem.com	purvi.shah@alkem.com
+91-98925 90003	+91-84337 00890